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Abstract
Background: Tobacco smoking is a risk factor for age-related macular degeneration, but studies
of ex-smokers suggest quitting can reduce the risk.
Methods: We fitted a function predicting the decline in risk of macular degeneration after quitting
to data from 7 studies involving 1,488 patients. We assessed the cost-effectiveness of smoking
cessation in terms of its impact on macular degeneration-related outcomes for 1,000 randomly
selected U.S. smokers. We used a computer simulation model to predict the incidence of macular
degeneration and blindness, the number of quality-adjusted life-years (QALYs), and direct costs (in
2004 U.S. dollars) until age 85 years. Cost-effectiveness ratios were based on the cost of the
Massachusetts Tobacco Control Program. Costs and QALYs were discounted at 3% per year.
Results: If 1,000 smokers quit, our model predicted 48 fewer cases of macular degeneration, 12
fewer cases of blindness, and a gain of 1,600 QALYs. Macular degeneration-related costs would
decrease by $2.5 million if the costs of caregivers for people with vision loss were included, or by
$1.1 million if caregiver costs were excluded. At a cost of $1,400 per quitter, smoking cessation
was cost-saving when caregiver costs were included, and cost about $200 per QALY gained when
caregiver costs were excluded. Sensitivity analyses had a negligible impact. The cost per quitter
would have to exceed $77,000 for the cost per QALY for smoking cessation to reach $50,000, a
threshold above which interventions are sometimes viewed as not cost-effective.
Conclusion: Smoking cessation is unequivocally cost-effective in terms of its impact on age-related
macular degeneration outcomes alone.
Background
There is a strong association between tobacco smoking
and age-related macular degeneration.[1] A pooled analy-
sis of data from the 3 largest population-based prevalence
surveys found risks for current smokers relative to never
smokers were 4.55-fold higher for neovascular age-related
macular degeneration and 2.54-fold higher for geographic
atrophy.[2] These relative risks were approximately halved
in ex-smokers, suggesting that the adverse effect of smok-
ing is reversible.[1,2] Despite these findings, the manage-
ment of macular degeneration has focused on treatment
rather than prevention.
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Previous analyses of the economics of smoking cessation
have considered the improved quality of life, increased
life expectancy and lower health care expenditures associ-
ated with the reduced incidence of illnesses such as cardi-
ovascular disease, stroke, lung cancer and chronic
obstructive pulmonary disease. [3-5] These analyses have
found that interventions that encourage and facilitate
quitting are very cost-effective, with net cost savings in
some instances.[5] However the economic impact of quit-
ting on macular degeneration has not been analysed.
The purpose of the present analysis was therefore to quan-
tify the health and health economic benefits of smoking
cessation in relation to age-related macular degeneration
alone. We estimated the cost-effectiveness of a tobacco
control program in terms of prevention of blindness and
improvement in quality of life as a consequence of the
decreased risk of macular degeneration. We based our esti-
mates of the cost of quitting on the Massachusetts
Tobacco Control program conducted in the 1990s, and
which had the highest per capita expenditure on tobacco
control in the world.[6] Our analyses investigated the
extent to which the cost of such smoking cessation pro-
grams will be offset by savings in the cost of care and med-
ical treatment due to prevention of vision loss.
Methods
Model Overview
We developed a Markov model to simulate the risk and
progression of macular degeneration in cigarette smokers
and quitters in the United States, my modifying a Markov
model we had published previously.[7] The previous
model was designed to assess the cost-effectiveness of
ranibizumab, a new treatment for the neovascular form of
macular degeneration. Both it, and the model reported
here, were programmed using the decision analysis soft-
ware TreeAge.[8] The smoking and macular degeneration
model predicted the following outcomes for smokers and
quitters: the probability of developing macular degenera-
tion, the probability of blindness (defined as visual acuity
< 35 letters read on the logMAR chart, or Snellen equiva-
lent < 20/200),[9] the number of years spent blind (blind-
years), the number of quality-adjusted life-years (QALYs),
and direct costs (excluding patient time and travel costs)
from a societal perspective in 2004 U.S. dollars.
The Markov model tracked subjects in each 5-year age
group from 15–19 years for the remainder of their life-
time, censored at age 85 years. Each year, subjects were at
risk of developing either the neovascular or the geo-
graphic atrophy form of macular degeneration, or dying.
The neovascular form (or "wet" age-related macular
degeneration) involves serous or haemorrhagic detach-
ment of the retinal pigment epithelium or sub-retinal pig-
ment epithelial haemorrhages. Geographic atrophy (or
"dry" age-related macular degeneration) involves a dis-
crete area of retinal depigmentation with a sharp border
and visible choroidal vessels. Disease progression for sub-
jects who developed macular degeneration was character-
ized by a series of annual transitions between health
states, defined by visual acuity, as described in our previ-
ous paper.[7] Briefly, the five health states considered cor-
responded to the number of letters read on the log-MAR
chart[9] being > 85, 70–80, 55–65, 40–50, and < 35
(blind). We assumed that, each year, a patient's visual acu-
ity would increase by 15 letters, remain the same, decrease
by 15 letters, or decrease by 30 letters. We assumed that
smoking cessation decreased the risk of developing macu-
lar degeneration and the risk of death from all causes, but
did not affect disease progression. For each 5-year age-
group, for males and females separately, the course of
10,000 smokers was simulated one at a time, firstly
assuming that each subject continued to smoke, then
assuming that all subjects quit.
We assessed the macular degeneration-related benefits of
smoking cessation by comparing outcomes for a hypo-
thetical cohort of 1,000 smokers. This cohort was ran-
domly selected, stratified by 5-year age-group and sex,
from a population simulated to represent the U.S. popu-
lation of smokers in 2004.[10] Cost-effectiveness ratios
were estimated using data on the cost of smoking cessa-
tion from the comprehensive Massachusetts Tobacco
Control Program, conducted in the 1990s.[6] Future
costs, blind-years and QALYs were discounted at 3% per
year.[11]
Estimates for model variables
Incidence of age-related macular degeneration in smokers
Annual incidence probabilities for each form of age-
related macular degeneration for the general U.S. popula-
tion (i.e. for smokers, ex-smokers and never-smokers
combined) were based on the 5-year incidence of late age-
related maculopathy in the Beaver Dam Eye Study,[12]
and the proportions of geographic atrophy and neovascu-
lar age-related macular degeneration estimated in a
pooled analysis of incidence studies from the U.S., the
Netherlands and Australia.[13] We used a method previ-
ously described [4] to estimate probabilities for smokers
from these population probabilities. Briefly, the popula-
tion probabilities were adjusted on the basis of 2004–
2005 smoking prevalence in the U.S.,[10] and the relative
risks of each type of age-related macular degeneration in
smokers and ex-smokers estimated from pooled incidence
data (see Table 1).[2]
Incidence of age-related macular degeneration in quitters
Through a comprehensive MEDLINE search combining
the search terms "smoking" and "macular degeneration",
we identified 7 studies that reported the risk of age-relatedCost Effectiveness and Resource Allocation 2008, 6:18 http://www.resource-allocation.com/content/6/1/18
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macular degeneration for ex-smokers by time since quit-
ting: 2 prospective cohort studies,[14,15] 2 case-control
studies[16,17], and 3 cross-sectional studies. [18-20]
These studies analysed the smoking profiles of a total of
1,488 people with age-related macular degeneration. We
extracted data on the relative risk of age-related macular
degeneration for ex-smokers relative to never-smokers
and the time after quitting that each risk was assessed. In
the study by Seddon et al.[15] risks were reported relative
to current-smokers, and we therefore divided them by the
risks for never-smokers relative to current-smokers to
obtain risks for ex-smokers relative to never smokers.
Where time was reported in the publication as a range, we
took the time since quitting to be the midpoint; for exam-
ple, < 20 years and 5 – 14 years were recorded as 10 years.
Where time was reported as "greater than" or "equal or
greater than" a specified number of years, we took the
time since quitting to be the specified time plus 10 years,
so > 20 years and ≥ 20 years were recorded as 30 years.
We assumed the following model for the risk, RR(t), of
age-related macular degeneration for ex-smokers relative
to never-smokers:
RR(t) = [(RR0- 1)]e-t/τ + 1
where:
RR0 was the relative risk of developing age-related macular
degeneration for current-smokers versus never-smokers
t was the time, in months, since quitting
τ was a slope parameter that was inversely proportional to
the rate at which the relative risk decreased with time since
quitting.
We assumed that the asymptotic value of the relative risk,
RR(∞), was 1, i.e., that the risk of developing macular
degeneration for quitters eventually equalled the risk for
never-smokers. The data from the 7 studies were consist-
ent with this assumption. Six of the 7 studies had a RR
measured or inferred at 30 years, and values ranged from
0.85 to 1.5. We assumed that RR0 depended on the partic-
ular study population and the type of macular degenera-
tion (neovascular or geographic atrophy). A separate
value for RR0 was therefore estimated for each study. How-
ever, due to the paucity of data, we assumed that the
parameter τ did not depend on age, or sex, or the type of
macular degeneration.
The values of RR0 and τ were estimated by fitting the non-
linear model:
ln(RR(t)) = ln([(RR0- 1)]e-t/τ + 1) + ε
where the regression errors (ε) were assumed to be inde-
pendent.
The analyses were carried out using the non-linear regres-
sion procedure (Levenberg-Marquardt estimation
method) in the SPSS software package. The natural loga-
rithms of the relative risks were weighted proportional to
the inverse of their variances, which were estimated from
the reported confidence intervals for the relative risks. As
confidence intervals were unavailable for the relative risks
calculated from the data reported by Seddon and col-
leagues,[15] the variances of the natural logarithms of the
relative risks were conservatively estimated by summing
the variances of the natural logarithms of the risks of ex-
smokers relative to current-smokers and those of never-
smokers relative to current-smokers.[21]
Table 1: Annual incidence probabilities of age-related macular degeneration for current smokers and ex-smokers who quit 15 years 
previously*
Type of age-related macular degeneration and age range Smoker (per 1000)† Quitter (per 1000)‡
Neovascular
< 55 years 0.00 0.00
55–64 years 0.86 0.73
65–74 years 4.50 3.84
75–84 years 20.61 17.60
Geographic atrophy
< 55 years 0.00 0.00
55–64 years 0.39 0.23
65–74 years 1.86 1.11
75–84 years 8.09 4.83
* Men and women combined
† Estimated[4] from Beaver Dam Eye Study incidence data,[12] U.S. smoking prevalence in 2004–2005[10] and the relative risks of age-related 
macular degeneration for smokers and ex-smokers relative to never-smokers.[2]
‡ Estimated according to the relative risk functions plotted in Figure 2.Cost Effectiveness and Resource Allocation 2008, 6:18 http://www.resource-allocation.com/content/6/1/18
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The estimated value of τ was 165, with an asymptotic
standard error of 35, and 95% Confidence Interval of 90
– 241. The model therefore predicted that every 9.5 years
(95% confidence interval: 5.2 – 13.9 years)the difference
between a quitter's risk of age-related macular degenera-
tion and that of a never-smoker will be halved, because
when t = ln(2)*τ, (RR(t)-1) = (RR0 - 1)/2k, where k is an
arbitrary integer. The data and the predicted decline over
time in risk of age-related macular degeneration for ex-
smokers relative to never-smokers are plotted in Figure 1.
For illustrative purposes, a common value of RR0 was
assumed for the fitted model, estimated by pooling the
data. A number of alternative models were run, excluding
observations in the first 10 years to mitigate any "sick
quitter" effect, and considering studies with younger sub-
jects and older subjects separately. These alternative mod-
els gave values of τ within the 95% confidence interval for
τ in the base model.
In our Markov model of the impact of smoking cessation
on age-related macular degeneration, we needed esti-
mates of the risks, for ex-smokers relative to current-smok-
ers, over time since quitting.
We therefore used the model parameter estimate that
describes the rate of decline in the relative risk, and the
risks of each type of macular degeneration for smokers rel-
ative to never-smokers[2] to calculate the risk, each year
after quitting, of neovascular macular degeneration and
geographic atrophy, for an ex-smoker relative to a current
smoker, using the following formulae.
By definition:
rr(t) = RR(t)/RR0
or
rr(t) = [(1-1/RR0)]e-t/τ + 1/RR0.
The values of RR0 (the risks of macular degeneration for
current smokers relative to never smokers) for neovascular
disease and geographic atrophy were assumed to be 4.55
(asymptotic 95% CI: 2.74 – 7.54) and 2.54 (asymptotic
95% CI: 1.25 – 5.17), respectively.[2]
Therefore, for neovascular age-related macular degenera-
tion:
Risk over time of age-related macular degeneration (AMD) for ex-smokers versus never-smokers Figure 1
Risk over time of age-related macular degeneration (AMD) for ex-smokers versus never-smokers.Cost Effectiveness and Resource Allocation 2008, 6:18 http://www.resource-allocation.com/content/6/1/18
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rr(t) = 0.220 e-t/165 + 0.780
and, for geographic atrophy:
rr(t) = 0.606 e-t/165 + 0.394
The predicted declines in these risks over time are shown
in Figure 2. The incidence probabilities for smokers were
multiplied by these relative risks to obtain incidence prob-
abilities for ex-smokers, and such probabilities 15 years
after quitting are presented in Table 1.
Progression, treatment and costs of age-related macular 
degeneration
Our assumptions about the distribution of visual acuity at
diagnosis of age-related macular degeneration, disease
progression, treatment and costs came from a previous
paper in which we analysed the cost-effectiveness of
ranibizumab, a new treatment for the neovascular form of
macular degeneration.[7]
We assumed that 90% of patients with the neovascular
form of disease were treated with ranibizumab, that
ranibizumab's cost was the current wholesale price
($1,950 per dose)[22]and that its effectiveness and dosing
regimen corresponded to the base-case scenario described
in the previous paper,[7] i.e. it was effective for 4 years,
during which time it was given monthly for the first 2
years then 3 monthly. Costs for geographic atrophy-
related medical care (which were not considered in the
ranibizumab cost-effectiveness analysis) were sourced
from Halpern and colleagues' analyses of Medicare
files.[23] We converted the average annual cost for
patients with "dry only" disease ($345 in 2001 dollars) to
2004 U.S. dollars ($395) using the medical care Con-
sumer Price Index.[24]
Utilities
We assumed vision loss was associated with reduced qual-
ity of life, and used the visual acuity-specific utility esti-
mates from patients with age-related macular
degeneration sourced for the ranibizumab cost-effective-
ness analysis.[7,25] We assumed there was no reduction
in utility associated with smoking or quitting.
Probabilities of death for smokers and quitters
We used the method previously described, [4] and
referred to above for the incidence of macular degenera-
tion in smokers, to estimate probabilities of death for
smokers from all causes mortality data for the general U.S.
population in 2004.[26] Smoking prevalence in 2004–
5[10] and relative risks of all causes mortality for smokers
from the American Cancer Society (ACS) Cancer Preven-
Predicted declines over time after smoking cessation in the Relative Risk (RR) of neovascular age-related macular degeneration  (AMD) and geographic atrophy, for ex-smokers compared with smokers Figure 2
Predicted declines over time after smoking cessation in the Relative Risk (RR) of neovascular age-related macular degeneration 
(AMD) and geographic atrophy, for ex-smokers compared with smokers.
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tion Study (CPS-II) the U.S.[27] were used in the calcula-
tions.
Quitters' mortality probabilities were estimated by apply-
ing a function that described the decline in the risk of
death from all causes for quitters relative to smokers[4] to
the probability of death for smokers. The function was
based on data from the ACS CPS-II. [27]
Cost per quitter
The Massachusetts tobacco control program started in
1993, and spent over $200 million by 1999 on interven-
tions including a mass media campaign, services such as
treatment and telephone counselling to help smokers
quit, and promotion of local policies.[6] By 1999, the
adult smoking prevalence in Massachusetts was 3.9%
lower than in 48 other U.S. states without such pro-
grams.[6,28] This represented about 183,600 fewer adult
smokers, based on the number of people aged 18 and over
in Massachusetts in 1999.[29] The cost per quitter was
therefore assumed to be $1,400 after adjusting the cost of
the program (assumed to be in 1995 U.S. dollars) to 2004
dollars on the basis of the Consumer Price Index.[30]
Sensitivity analyses
We performed sensitivity analyses to investigate the
impact of key model assumptions on QALYs, costs and
the incremental cost per QALY gained. The parameter that
describes the rate of decline in risk of macular degenera-
tion after quitting was varied from its low to its high 95%
confidence limit, and different assumptions about the dis-
utility of vision loss and treatment of neovascular age-
related macular degeneration[7] were investigated. A
threshold analysis was conducted to determine the cost
per quitter that gave a cost per QALY for smoking cessa-
tion of $50,000.
Results
The expected lifetime macular degeneration-related
health outcomes for 1000 randomly selected smokers,
who either continued to smoke or quit, are summarized
in Table 2. Our model predicted that quitters would have
48 fewer cases of macular degeneration than continuing
smokers, leading to 12 fewer cases of blindness, 21 fewer
blind-years and 1,611 more QALYs.
The lifetime macular degeneration-related costs and cost-
effectiveness ratios associated with smoking cessation are
summarized in Table 3. When the costs of caregivers for
people with macular degeneration and vision loss were
included in the analysis, the costs for 1000 quitters were
about $2.52 million lower than those for 1000 continuing
smokers. At a cost per quitter of $1,400, quitting was
"dominant" in terms of macular degeneration outcomes
alone, i.e. it was both cost saving and improved health.
Although quitting was no longer dominant when the cost
of caregiving was excluded from the analysis, the incre-
mental cost per QALY gained through quitting was only
$197.
In the sensitivity analyses, quitting smoking remained
dominant under all assumptions tested, when caregiver
costs were included in the analyses and the cost per quitter
was $1,400. The sensitivity analyses excluding caregiver
costs are summarized in Table 4. The cost-effectiveness
ratios were all still considerably less than $1,000 per
QALY. The cost per quitter had to exceed $77,000 for the
incremental cost per QALY associated with smoking cessa-
tion to reach $50,000.
Discussion
The 2004 U.S. Surgeon General's report concluded that
the available evidence was suggestive of a causal relation-
ship between smoking and both neovascular and atrophic
Table 2: Expected Lifetime* AMD-related† Health Outcomes for 1,000 Randomly Selected Smokers,‡ who either Continue Smoking or 
Quit.
AMD-related Health Outcomes Continuing Smokers Quitters Benefits of quitting
Mean s.e Mean s.e Mean s.e
Cases of AMD
Neovascular 86 0.6 45 0.4 -41 0.7
Geographic Atrophy 34 0.4 27 0.3 -7 0.5
Total 120 0.7 72 0.5 -48 0.9
Cases of blindness§ 32 0.4 20 0.3 -12 0.5
Blind-years 75 1.2 54 1.1 -21 1.6
QALYs 19,168 10 20,778 9 1,611 14
s.e = standard error
* Censored at age 85 years
† AMD: Age-related macular degeneration
‡ From the U.S. population of smokers in 2004–2005[10]
§ Visual acuity ≤ 20/200 (logMAR equivalent ≤ 35 letters)Cost Effectiveness and Resource Allocation 2008, 6:18 http://www.resource-allocation.com/content/6/1/18
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age-related macular degeneration,[31] and summarized 3
biologic mechanisms whereby smoking might exacerbate
or accelerate the degenerative changes that occur in the
macula with age. A subsequent review, that included 5
additional studies, confirmed a strong association
between current smoking and age-related macular degen-
eration which fulfilled accepted causality criteria, and
concluded that there was evidence of reversibility.[1] We
Table 3: Expected Lifetime* AMD-related† Costs for 1,000 Randomly Selected Smokers‡ who either Continue Smoking or Quit, and 
Cost-Effectiveness Ratios for a Tobacco Control program.§.
Cost 
assumptions
Lifetime AMD-related costs Cost-effectiveness Ratios 
(assuming a cost per quitter of $1,400)
Continuing 
Smokers
Quitters Benefit of 
quitting
Cost per case of 
blindness 
prevented
Cost per blind-
year prevented
Cost per QALY 
gained
$ 
mean (s.e)
$
mean (s.e)
$
mean (s.e)
$$$
Including 
caregiver costs
7,810,000 (73,080) 5,286,000 (64,520) -2,523,000 
(97,490)
Dominant¶ Dominant Dominant
Excluding 
caregiver costs
2,786,000 (19,830) 1,703,000 (15,930) -1,082,000 
(25,440)
26,500 15,142 197
s.e = standard error
* Censored at age 85 years
† AMD: Age-related macular degeneration
‡ From the U.S. population of smokers in 2004–2005[10]
§Costs are in 2004 U.S. dollars and were rounded. Costs, blind-years and QALYs were discounted at 3% per annum
¶ Dominant: Quitting improved health outcomes and was cost saving.
Table 4: Sensitivity Analyses of the Lifetime* AMD-related† Benefits of Quitting for 1,000 Randomly Selected Smokers‡, and Cost-
Effectiveness of a Tobacco Control Program.§.
Model Variable Lifetime AMD-related Benefits of Quitting Cost per QALY gained 
(assuming a cost per quitter of $1,400)
QALYs gained Costs (excluding caregivers) $ $
Slope parameter (τ), which is 
inversely proportional to the rate of 
decline in the risk of AMD after 
quitting relative to current-smokers
Upper 95% confidence Limit 
(slower decline)
1,600 -774,000 391
Lower 95% confidence Limit 
(faster decline)
1,623 -1,426,000 Dominant
Higher utilities for reduced visual 
acuity¶
1,600 -1,082,000 199
Ranibizumab treatment of neovascu-
lar AMD||
Base-case scenario, as in Table 3, but:
low ranibizumab cost 1611 -360,000 645
50% of neovascular patients treated 1613 -732,000 414
Sustained-effect scenario, low 
ranibizumab cost
1610 -282,000 694
Non-sustained effect scenario, high 
ranibizumab cost
1611 -929,000 292
* Censored at age 85 years
† AMD: Age-related macular degeneration
‡ From the U.S. population of smokers in 2004–2005[10]
§Costs are in 2004 U.S. dollars and were rounded. Costs, blind-years and QALYs were discounted at 3% per annum
¶Source: Brown et al., estimated with standard gamble method.[25] For 30 letters read, for example, utility = 0.71, rather than 0.52 in the base 
case.
|| Base-case, Sustained-effect and Non-sustained effect scenarios as defined in previous paper.[7] Low ranibizumab cost = bevazicumab price ($50 
per dose). High ranibizumab price = wholesale price ($1,950 per dose).Cost Effectiveness and Resource Allocation 2008, 6:18 http://www.resource-allocation.com/content/6/1/18
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quantified the reduction in risk over time since quitting
smoking, using data from 7 studies involving 1,488 peo-
ple with age-related macular degeneration. [14-20]
Although none of the studies monitored the incidence of
macular degeneration prospectively in ex-smokers from
the time of quitting, all studies found a reduced risk 10
years or more after ex-smokers reported having quit.
We assessed the benefits of smoking cessation in terms of
the reduced incidence, morbidity and direct costs of age-
related macular degeneration experienced by ex-smokers
compared with smokers. In order to concentrate attention
on macular degeneration, the numerous other benefits
associated with quitting, such as morbidity reductions
and health care cost savings associated with lower risks of
myocardial infarction, stroke, lung cancer and chronic
obstructive pulmonary disease, were not considered.[4]
The reduction in all causes mortality risk consequential to
quitting was incorporated into the model in order to accu-
rately estimate the macular degeneration-related QALY
gain associated with smoking cessation, but gains in life
expectancy were not estimated. Our model predicted that
smoking cessation was cost-effective even when only its
impact on macular degeneration and mortality were con-
sidered. This finding was robust to all plausible variations
in the model parameter estimates. Even assuming the
slowest rate of decline in the risk of age-related macular
degeneration after quitting, the incremental cost per
QALY gained in 1,000 randomly selected smokers who
quit was only $391.
Many effective interventions are available to encourage
and assist smokers to quit. These include clinical treat-
ments and services, such as counseling and pharmaco-
therapies,[32] population-based interventions, such as
mass-media anti-smoking advertising and telephone sup-
port (quit lines),[33] and policies, such as increasing the
price of tobacco products or smoking bans and restric-
tions.[34] We based our analysis on an estimated cost per
quitter for the comprehensive Massachusetts Tobacco
Control Program, which comprised treatment services, a
mass media campaign, a tobacco surcharge and other
local policies.[6] A wide range of costs per quitter have
been reported for smoking cessation interventions,
reflecting differences in the efficiency of interventions as
well as differences in evaluation methodology.[35] A
recent review standardized evaluations of clinical inter-
ventions, by adjusting cost-effectiveness ratios to reflect a
societal perspective and comply with guidelines for eco-
nomic evaluation.[36] Of the treatments considered, nic-
otine replacement therapy plus counseling, compared
with counseling alone, had the highest incremental cost
per quitter. The average adjusted cost per quitter in 4 stud-
ies was $9,100 in 2002 U.S. dollars. Much lower cost-
effectiveness ratios have been reported for population-
based interventions and policies. For example, adjusted
costs per quitter of $298 – $1,593 (1997 U.S. dollars) for
mass media education campaigns to promote smoking
cessation were calculated by the Task Force on Commu-
nity Preventive Services,[33] smoke-free workplace poli-
cies were found to cost $799 per quitter (2002 U.S.
dollars),[37] and the American Cancer Society's tele-
phone counseling service cost $1,300 per quitter (2000
U.S. dollars). All these cost-effectiveness ratios are consid-
erably lower than the threshold cost we calculated of
$77,000 per quitter, above which the incremental cost per
QALY associated with smoking cessation exceeds
$50,000. This indicates that our finding that smoking ces-
sation is cost-effective in terms of its impact on macular
degeneration alone is also robust to plausible variation in
the cost per quitter, and can be generalized to most, if not
all, tobacco control strategies.
In a previous paper, we assessed the cost-effectiveness of
ranibizumab, a new therapy for the most common type of
age-related macular degeneration.[7] Ranibizumab is the
first treatment for age-related macular degeneration that
improves visual acuity and its efficacy has been described
as miraculous.[38] Over time horizons of 2 to 10 years we
found that ranibizumab had incremental costs per QALY
that would support description of the treatment as "cost-
effective".[7] Health care funding bodies have also con-
cluded that ranibizumab's cost-effectiveness is acceptable.
It has been recommended by NICE in the United King-
dom,[39] and subsidized by the Australian government
under its Pharmaceutical Benefits Scheme.[40] In this
paper, we assessed the cost-effectiveness of smoking cessa-
tion as a strategy to prevent macular degeneration over a
different time period from the ranibizumab analysis – the
remaining lifetime of a quitter, censored at age 85 –
because the benefits of quitting accrue gradually over a
long time period. We found that smoking cessation was
unequivocally cost-effective in terms of age-related macu-
lar degeneration outcomes. Our model predicted gains in
QALYs, and savings in the cost of macular degeneration
treatment and the cost of care for people with impaired
vision. Our findings have two potential practical applica-
tions. First, they will hopefully prompt ophthalmologists,
who prescribe ranibizumab, to encourage patients to quit
smoking in the interests of their sight. Second, our analy-
sis will provide tobacco control advocates seeking govern-
ment funding for anti-smoking programs with evidence
that such programs are as justifiable on cost-effectiveness
grounds as the newly available treatment for macular
degeneration.
Conclusion
This analysis strongly supports the implementation of
smoking cessation interventions to prevent age-relatedCost Effectiveness and Resource Allocation 2008, 6:18 http://www.resource-allocation.com/content/6/1/18
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macular degeneration, because of their unequivocal cost-
effectiveness.
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